Short-Term Malignancy Risk of JAK Inhibitors in Severe Alopecia Areata: A Multicenter Cohort Study
May 2025
in “
Archives of Dermatological Research
”
Research cited in this study
4 / 4 resultsresearch Alopecia Areata and Malignancies: Uncertainties Clarified by a Large-Scale Population-Based Study
A large-scale study involving 51,561 patients with alopecia areata (AA) and 51,410 controls found that AA is significantly associated with hematological malignancies (HMs), particularly non-Hodgkin lymphoma, but not with solid malignancies (SMs), except in cases of alopecia totalis and universalis. The association with HMs was stronger in patients with late-onset AA (≥ 50 years). The study suggests a need for further research to confirm these findings in other populations.
research Janus Kinase Inhibitors For Alopecia Areata
JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
research Cancer Risk in Patients with Alopecia Areata: A Nationwide Population-Based Matched Cohort Study
Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
Related Research
1 / 1 results
research Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child
A child with rough nails also had hair loss and allergies.